Spectral Medical Inc. announced a major milestone by reaching its Interim Enrollment target of patient 90 in its TIGRIS trial. Under the terms of the Company?s Exclusive Distribution Agreement with Baxter International(?Baxter?), at Interim Enrollment, Baxter has the option to make a second milestone payment to Spectral to maintain its PMX exclusive distribution rights. As such, Spectral has formally notified Baxter of reaching its Interim Enrollment target of 90 patients.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.48 CAD | 0.00% | +11.63% | +12.94% |
Apr. 10 | Spectral Medical Updated on Tigris Trial | MT |
Apr. 10 | Spectral Medical Brief: Providing Tigris Trial Update; 101 patients enrolled | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+12.94% | 97.97M | |
+25.92% | 661B | |
+26.74% | 566B | |
-6.52% | 352B | |
+20.39% | 332B | |
+3.13% | 283B | |
+13.45% | 231B | |
+4.70% | 200B | |
-9.41% | 195B | |
-5.11% | 145B |
- Stock Market
- Equities
- EDT Stock
- News Spectral Medical Inc.
- Spectral Medical Announces Major Milestone by Reaching Its Interim Enrollment Target of 90 Patients